Albert F G Leentjens1. 1. Department of Psychiatry, Maastricht University Hospital, PO Box 5800, 6202 AZ, the Netherlands. a.leentjens@np.unimaas.nl
Abstract
BACKGROUND: Depression frequently accompanies Parkinson's disease (PD) and may have a negative impact on activities of daily living, cognitive performance, and quality of life. Because of the symptom overlap between the 2 disorders, it may be difficult to recognize depression in PD. Moreover, the partially shared pathophysiology may make it difficult to treat depressive symptoms without influencing motor or cognitive function. OBJECTIVE: To review the current knowledge of the epidemiology, etiology, pathophysiology, and treatment of depression in patients with Parkinson's disease. METHOD: Discussion of recent studies and relevant literature. CONCLUSION: Not only conceptually but also in terms of etiology, pathophysiology, and treatment, the relationship between PD and depression remains a challenge. There are still many questions to be answered. In the therapeutic domain, large, placebo-controlled trials are necessary to evaluate the efficacy of antidepressant treatment and allow the development of evidence-based guidelines.
BACKGROUND:Depression frequently accompanies Parkinson's disease (PD) and may have a negative impact on activities of daily living, cognitive performance, and quality of life. Because of the symptom overlap between the 2 disorders, it may be difficult to recognize depression in PD. Moreover, the partially shared pathophysiology may make it difficult to treat depressive symptoms without influencing motor or cognitive function. OBJECTIVE: To review the current knowledge of the epidemiology, etiology, pathophysiology, and treatment of depression in patients with Parkinson's disease. METHOD: Discussion of recent studies and relevant literature. CONCLUSION: Not only conceptually but also in terms of etiology, pathophysiology, and treatment, the relationship between PD and depression remains a challenge. There are still many questions to be answered. In the therapeutic domain, large, placebo-controlled trials are necessary to evaluate the efficacy of antidepressant treatment and allow the development of evidence-based guidelines.
Authors: Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers Journal: Neuropsychology Date: 2011-12-05 Impact factor: 3.295
Authors: Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern Journal: J Neuropsychiatry Clin Neurosci Date: 2006 Impact factor: 2.198
Authors: Daniel Weintraub; Knashawn H Morales; John E Duda; Paul J Moberg; Matthew B Stern Journal: Parkinsonism Relat Disord Date: 2006-06-22 Impact factor: 4.891
Authors: Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz Journal: Mov Disord Date: 2007-06-15 Impact factor: 10.338
Authors: Lori M Gorton; Marta G Vuckovic; Nina Vertelkina; Giselle M Petzinger; Michael W Jakowec; Ruth I Wood Journal: Behav Brain Res Date: 2010-05-21 Impact factor: 3.332
Authors: Amy H Farabaugh; Joseph J Locascio; Liang Yap; Maurizio Fava; Stella Bitran; Jessica L Sousa; John H Growdon Journal: Ann Clin Psychiatry Date: 2011-08 Impact factor: 1.567